SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated October 12, 2023, details a material definitive agreement and unregistered sales of equity securities by BioSig Technologies, Inc. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM. The report covers events occurring on October 12, 2023, and references an engagement agreement dated July 26, 2023.
Key Financial Metrics and Transaction Details
The filing discloses a private placement transaction (the "October PIPE") with the following specific metrics:
- Gross Proceeds: $597,496.72
- Common Shares Sold: 1,129,996 shares
- Share Purchase Price: $0.52876 per share
- Warrants Issued to Investors: 564,998 warrants (to purchase 564,998 shares)
- Warrant Exercise Price: $0.46626 per share
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance.
- Advisor Compensation: A warrant to purchase 84,750 shares issued to Laidlaw & Company (UK) Ltd. at an exercise price of $0.46626 per share.
The filing does not provide data on revenue, profit, cash flow, operating margins, total debt, or liquidity positions beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding equity and potential dilution resulting from the issuance of 1,129,996 shares of common stock and 649,748 total warrants (564,998 to investors and 84,750 to the financial advisor). The company received approximately $597,500 in gross proceeds to support its operations.
Outlook, Risks, and Contingencies
The transaction was conducted in reliance on exemptions from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933. The filing notes that the Purchase Agreement contains standard representations, warranties, and covenants. No specific forward-looking guidance, management commentary on future performance, or discussion of unusual items is included in this report.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the use of the $597,496.72 gross proceeds as disclosed in subsequent filings.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the exercise of the 649,748 warrants issued, which could further dilute shareholders if exercised.